Bibliography
- Krag A, Borup T, Moller S, et al. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105-40
- Martin-Llahi M, Pepein MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9
- Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64
- Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 2003;98:1338-44
- Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;23:588-95
- Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
- Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000;11:406-10
- Maybauer MO, Maybauer DM, Enkhbaatar P, et al. Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 2008;22:253-63
- Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 – receptor physiology. Crit Care 2003;7:427-34
- Barret LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40
- Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006;40:2170-7
- Forsling ML, Aziz LA, Miller M, et al. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 1980;85:237-44
- Nilsson G, Lindblom P, Ohlin M, et al. Pharmakinetics of terlipressin after single i.v. doses to healthy volunteers. Drug Exp Clin Res 1990;16:307-14
- Lange M, Ertmer C, Westphal M. Vasopressin vs terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008;34:821-32
- Ryckwaert F, Virsolvy A, Fort A, et al. Terlipressin, a pro-vasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009;37:876-81
- Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5
- Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8
- Scharte M, Meyer J, Van Aken H, et al. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001;29:1756-60
- Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003;31:215-20
- Lange M, Morelli A, Ertmer C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007;28:623-9
- Westphal M, Stubbe H, Sielenkamper AW, et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003;29:301-8
- O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-10
- Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004;30:597-604
- Albanese J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005;33:1897-902
- Leone M, Albanese J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004;22:314-19
- Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-93
- Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 2004;30:477-80
- Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, et al. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 2006;10:R20
- Zeballos G, Lopez-Herce J, Fernandez C, et al. Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 2006;68:151-3
- Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med 2008;34:511-17
- Klein M, Weksler N, Borer A, et al. Terlipressin facilitates transport of septic patients treated with norepinephrine. Isr Med Assoc J 2006;8:691-3
- Medel J, Boccara G, Van de Steen E, et al. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg 2001;93:53-5
- Schmitt W, Wagner-Thiessen E, Lux G. Ischemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastrenterology 1987;34:134-6
- Stephan F, Paillard F. Terlipressin-exacerbated hypokaliemia. Lancet 1998;351:1249-50
- Donnelan F, Cullen G, Hegarty JE, et al. Ischemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol 2007;64:550-2
- Morelli A, Tritapepe L, Rocco M, et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology 2005;102:12-9
- Lauzier F, Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006;32:1782-9
- Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008;100:494-503
- Patel BM, Chittok DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82
- Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock. A prospective, randomized, controlled study. Circulation 2003;107:2313-79
- Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87
- Singer M. Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol 2008;22:359-68
- Rivers E, Nguyen B, Havstad S, et al. Early goal-Directed Therapy Collaborative Group: early goal-directed therapy in the treatment of severe sepsis and septic shock. N Eng J Med 2001;345:1368-77
- Rivers EP, Kruse JA, Jacobsen G, et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med 2007;35:2016-24
- Jolley DH, De Keulenaer BL, Potter A, et al. Terlipressin infusion in catecholamine-resistant shock. Anaesth Intensive Care 2003;31:560-4
- Morelli A, Ertmer C, Lange M, et al. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med 2007;33:1669-70
- Umgelter A, Reindl W, Schmid RM, et al. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Med 2008;34:390-1
- Morelli A, Ertmer C, Lange M, et al. Continuous terlipressin versus vasopressin infusion in septic shock: the TERLIVAP study. Crit Care 2008;12(Suppl 2):P403
- Asfar P, Hauser B, Ivanyi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005;33:373-80
- Rehberg S, Ertmer C, Köhler G, et al. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009;35:1286-96
- Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-18
- Annane D. Vasopressin plus corticosteroids: the shock duo! Crit Care Med 2009;37:1126-7
- Traber D. Selective V1a receptor agonists in experimental septic shock. Crit Care 2007;11(Suppl 4):P51
- Laporte R, Russell J, Landry D, et al. The selective V1a receptor agonist FE 202158 reverses platelet activating factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Crit Care 2008;12(Suppl 2):P407